MedTrace Logo

Study Impact on Outcome of Eltrombopag in Elderly Patients with Acute Myeloid Leukemia Receiving Induction Chemotherapy

NCT03603795 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2024-10-29

No results posted yet for this study

Summary

Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction chemotherapy. A phase II multicenter and randomized placebo-controlled study

Conditions

Interventions

DRUG

Eltrombopag

Eltrombopag concomitant with induction chemotherapy in patient with AML

DRUG

Placebo

Placebo concomitant with induction chemotherapy patients with AML

Sponsors & Collaborators

Principal Investigators

  • Arnaud PIGNEUX, MD PD · French Innovative Leukemia Organization (FILO)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-11
Primary Completion
2022-06-15
Completion
2026-07-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03603795 on ClinicalTrials.gov